Preparation and investigation of arsenic trioxide-loaded polylactic acid/magnetic hybrid nanoparticles

Song, Xiaoli; You, Juan; Wang, Juan; Zhu, Aiping; Ji, Lijun; Guo, Rong

doi:10.1007/s40242-014-3306-9

Cited by 19 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 To improve the therapeutic efficacy of As 2 O 3 in cancer treatments, various drug delivery system (DDS) such as As 2 O 3 loaded polylactic acid(PLA)/magnetic nanoparticles, arsenic loaded multiple drug mesoporous silica nanoparticles and [Ni(HAsO 3 )]-loaded polymer-caged nanobin were conducted. [9][10][11] However, few of them focused on the features of the DDS in vivo. Therefore, our group explored the in vitro/vivo characteristics of ATO after it was loaded by functionalized DDS.…”

Section: Introductionmentioning

confidence: 99%

pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo

et al. 2016

View full text Add to dashboard Cite

Arsenic trioxide (As2O3, ATO), a FDA approved drug for hematologic malignancies, was proved of efficient growth inhibition of cancer cell in vitro or solid tumor in vivo. However, its effect on solid tumor in vivo was hampered by its poor pharmacokinetics and dose-limited toxicity. In this study, a polyacrylic acid capped pH-triggered mesoporous silica nanoparticles was conducted to improve the pharmacokinetics and enhance the antitumor effect of arsenic trioxide. The mesoporous silica nanoparticles loaded with arsenic trioxide was grafted with polyacrylic acid (PAA-ATO-MSN) as a pH-responsive biomaterial on the surface to achieve the release of drug in acidic microenvironment of tumor, instead of burst release action in circulation. The nanoparticles were characterized with uniform grain size (particle sizes of 158.6 ± 1.3 nm and pore sizes of 3.71 nm, respectively), historically comparable drug loading efficiency (11.42 ± 1.75%), pH-responsive and strengthened sustained release features. The cell toxicity of amino groups modified mesoporous silica nanoparticles (NH2-MSN) was significantly reduced by capping of polyacrylic acid. In pharmacokinetic studies, the half time (t1/2β) was prolonged by 1.3 times, and the area under curve) was increased by 2.6 times in PAA-ATO-MSN group compared with free arsenic trioxide group. Subsequently, the antitumor efficacy in vitro (SMMC-7721 cell line) and in vivo (H22 xenografts) was remarkably enhanced indicated that PAA-ATO-MSN improved the antitumor effect of the drug. These results suggest that the polyacrylic acid capped mesoporous silica nanoparticles (PAA-MSN) will be a promising nanocarrier for improving pharmacokinetic features and enhancing the anti-tumor efficacy of arsenic trioxide.

show abstract

Section: Introductionmentioning

confidence: 99%

pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Song et al [ 52 ] prepared magnetic core-polymer shell drug delivery system encapsulating ATO. The magnetic core employed was a small magnetic nanoparticle like Fe 3 O 4 and the shell was composed of a biocompatible and biodegradable polymer.…”

Section: Encapsulation Of Ato As a Single Agent Or Co-encapsulated Wimentioning

confidence: 99%

Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers

Akhtar¹,

Wang²,

Ghali³

et al. 2017

J Biomed Res

View full text Add to dashboard Cite

Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago, its anti-cancer properties for various malignancies have been under intense investigation. However, the clinical successes of arsenic trioxide in treating hematological cancers have not been translated to solid cancers. This is due to arsenic's rapid clearance by the body's immune system before reaching the tumor site. Several attempts have henceforth been made to increase its bioavailability toward solid cancers without increasing its dosage albeit without much success. This review summarizes the past and current utilization of arsenic trioxide in the medical field with primary focus on the implementation of nanotechnology for arsenic trioxide delivery to solid cancer cells. Different approaches that have been employed to increase arsenic's efficacy, specificity and bioavailability to solid cancer cells were evaluated and compared. The potential of combining different approaches or tailoring delivery vehicles to target specific types of solid cancers according to individual cancer characteristics and arsenic chemistry is proposed and discussed.

show abstract

“…They have been used to improvet he therapeutic effectso fa rsenic species in cancer therapy. [8][9][10] Despite the reported positive results of using nanocarriers for ATOd elivery,t he amounts of the carried drug were not too high with respect to the amount of the carrier materials used (see Ta ble 1). Moreover,t he ATOr elease from these nanocarriers was not well-definedt riggered or complete.…”

Section: Introductionmentioning

confidence: 99%

“…MOFs are crystalline materials composed of organic ligands andm etal ions or clusters, whichp rovide a huge variety of outstandingf unctional properties, [11,12] which enable versatile applicationsa sg as storage and separation, [13,14] catalysis, [15,16] sensing [17,18] and many others. [19] The well-defined pores and exceptionally high internal surface areas make them perfect candidates for drug carrierm aterials, polylactic acid/magnetic hybrid nanoparticles [8] 78-139 polyacrylic acid capped MSNs [9] 35 magnetite dopedM SNs [10] 111 metal-organic framework MFU-4l [20] (not pH-responsive) 237 metal-organic framework ZIF-8 [ because large amounts of drug molecules can be accommodated inside the pores within the whole materialv olume. Recently we reported on ap roof-of-principle study of using a MOF called MFU-4l as ac arrier materialo fa rsenic drugs.…”

Section: Introductionmentioning

confidence: 99%

“…These include polylactic acid/magnetic hybrid nanoparticles, polyacrylic acid capped mesoporous silica nanoparticles (MSNs) and magnetite doped mesoporous silica nanoparticles. They have been used to improve the therapeutic effects of arsenic species in cancer therapy . Despite the reported positive results of using nanocarriers for ATO delivery, the amounts of the carried drug were not too high with respect to the amount of the carrier materials used (see Table ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Zeolitic Imidazolate Framework‐8 as pH‐Sensitive Nanocarrier for “Arsenic Trioxide” Drug Delivery

Ettlinger

Moreno

Volkmer

et al. 2019

Chemistry A European J

View full text Add to dashboard Cite

Previous resultsr evealed that arsenic trioxide might be used as promising therapeutic agent for the treatment of some solid tumoursa sa typical teratoid rhabdoid tumours (ATRT). However,i no rder to becomea na pproved drug for solid tumour treatment, the active formulation has to get more efficient and feasible-buta tt he same time less toxic. One of the possibilities to achieve this dichotomy is to use nanomedicine tools. Herein, we report on the Znbased metal-organicf ramework ZIF-8 (Zeolitic Imidazolate Framework-8) which turned out to be ap romising candidate for the delivery of As III species. It conjointly features ah igh drug loading capacity and ap rominent pH-triggered release behaviour.A s III -loaded ZIF-8 nanoparticlesc oated and noncoatedw ith polyethylene glycol weres tudied by XRPD, IR, Raman, TGA, TEM, EDX, CHN-elemental analysis, sorption analysisa nd ICP-OES, and their cytotoxicity was evaluated in vitro.

show abstract

Preparation and investigation of arsenic trioxide-loaded polylactic acid/magnetic hybrid nanoparticles

Cited by 19 publications

References 23 publications

pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo

pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo

Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers

Zeolitic Imidazolate Framework‐8 as pH‐Sensitive Nanocarrier for “Arsenic Trioxide” Drug Delivery

Contact Info

Product

Resources

About